Chimeric hepatitis E virus-like particle as a carrier for oral-delivery

Pitchanee Jariyapong, Li Xing, Nienke E. van Houten, Tian Cheng Li, Wattana Weerachatyanukul, Benjamin Hsieh, Carlos G. Moscoso, Chun Chieh Chen, Masahiro Niikura, Holland H R Cheng

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Oral delivery with virus-like particles (VLPs) is advantageous because of the inherited entry pathway from their parental viral capsids, which enables VLP to withstand the harsh and enzymatic environment associated with human digestive tract. However, the repeat use of this system is challenged by the self-immunity. In order to overcome this problem, we engineered the recombinant capsid protein of hepatitis E virus by inserting p18 peptide, derived from the V3 loop of HIV-1 gp120, into the antibody-binding site. The chimeric VLP resembled the tertiary and quaternary structures of the wild type VLP and specifically reacted with an HIV-1 antibody against V3 loop. Different from the wild type VLP, the chimeric VLP was vulnerable to trypsin cleavage although it appeared as intact particle, suggesting that the intermolecular forces of attraction between the recombinant capsid proteins are strong enough to maintain the VLP icosahedral arrangement. Importantly, this VLP containing the V3 loop did not react with anti-HEV antibodies, in correspondence to the mutation at its antibody-binding site. Therefore, the insertion of peptides at the surface antigenic site could allow VLPs to escape pre-existing anti-HEV humoral immunity.

Original languageEnglish (US)
Pages (from-to)417-424
Number of pages8
JournalVaccine
Volume31
Issue number2
DOIs
StatePublished - Jan 2 2013

Fingerprint

Hepatitis E virus
virus-like particles
Virion
mouth
Antibody Binding Sites
Capsid Proteins
Human immunodeficiency virus 1
coat proteins
Recombinant Proteins
recombinant proteins
HIV-1
peptides
HIV Antibodies
Peptides
antibodies
capsid
Capsid
Humoral Immunity
humoral immunity
digestive tract

Keywords

  • Hepatitis E virus
  • HIV-1 epitope
  • Quaternary structure
  • Recombinant capsid protein
  • Trypsin proteolysis
  • Virus like particle

ASJC Scopus subject areas

  • Immunology and Microbiology(all)
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)
  • Molecular Medicine

Cite this

Jariyapong, P., Xing, L., van Houten, N. E., Li, T. C., Weerachatyanukul, W., Hsieh, B., ... Cheng, H. H. R. (2013). Chimeric hepatitis E virus-like particle as a carrier for oral-delivery. Vaccine, 31(2), 417-424. https://doi.org/10.1016/j.vaccine.2012.10.073

Chimeric hepatitis E virus-like particle as a carrier for oral-delivery. / Jariyapong, Pitchanee; Xing, Li; van Houten, Nienke E.; Li, Tian Cheng; Weerachatyanukul, Wattana; Hsieh, Benjamin; Moscoso, Carlos G.; Chen, Chun Chieh; Niikura, Masahiro; Cheng, Holland H R.

In: Vaccine, Vol. 31, No. 2, 02.01.2013, p. 417-424.

Research output: Contribution to journalArticle

Jariyapong, P, Xing, L, van Houten, NE, Li, TC, Weerachatyanukul, W, Hsieh, B, Moscoso, CG, Chen, CC, Niikura, M & Cheng, HHR 2013, 'Chimeric hepatitis E virus-like particle as a carrier for oral-delivery', Vaccine, vol. 31, no. 2, pp. 417-424. https://doi.org/10.1016/j.vaccine.2012.10.073
Jariyapong P, Xing L, van Houten NE, Li TC, Weerachatyanukul W, Hsieh B et al. Chimeric hepatitis E virus-like particle as a carrier for oral-delivery. Vaccine. 2013 Jan 2;31(2):417-424. https://doi.org/10.1016/j.vaccine.2012.10.073
Jariyapong, Pitchanee ; Xing, Li ; van Houten, Nienke E. ; Li, Tian Cheng ; Weerachatyanukul, Wattana ; Hsieh, Benjamin ; Moscoso, Carlos G. ; Chen, Chun Chieh ; Niikura, Masahiro ; Cheng, Holland H R. / Chimeric hepatitis E virus-like particle as a carrier for oral-delivery. In: Vaccine. 2013 ; Vol. 31, No. 2. pp. 417-424.
@article{484e9d3a5d724316840c79b3249f7bc4,
title = "Chimeric hepatitis E virus-like particle as a carrier for oral-delivery",
abstract = "Oral delivery with virus-like particles (VLPs) is advantageous because of the inherited entry pathway from their parental viral capsids, which enables VLP to withstand the harsh and enzymatic environment associated with human digestive tract. However, the repeat use of this system is challenged by the self-immunity. In order to overcome this problem, we engineered the recombinant capsid protein of hepatitis E virus by inserting p18 peptide, derived from the V3 loop of HIV-1 gp120, into the antibody-binding site. The chimeric VLP resembled the tertiary and quaternary structures of the wild type VLP and specifically reacted with an HIV-1 antibody against V3 loop. Different from the wild type VLP, the chimeric VLP was vulnerable to trypsin cleavage although it appeared as intact particle, suggesting that the intermolecular forces of attraction between the recombinant capsid proteins are strong enough to maintain the VLP icosahedral arrangement. Importantly, this VLP containing the V3 loop did not react with anti-HEV antibodies, in correspondence to the mutation at its antibody-binding site. Therefore, the insertion of peptides at the surface antigenic site could allow VLPs to escape pre-existing anti-HEV humoral immunity.",
keywords = "Hepatitis E virus, HIV-1 epitope, Quaternary structure, Recombinant capsid protein, Trypsin proteolysis, Virus like particle",
author = "Pitchanee Jariyapong and Li Xing and {van Houten}, {Nienke E.} and Li, {Tian Cheng} and Wattana Weerachatyanukul and Benjamin Hsieh and Moscoso, {Carlos G.} and Chen, {Chun Chieh} and Masahiro Niikura and Cheng, {Holland H R}",
year = "2013",
month = "1",
day = "2",
doi = "10.1016/j.vaccine.2012.10.073",
language = "English (US)",
volume = "31",
pages = "417--424",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "2",

}

TY - JOUR

T1 - Chimeric hepatitis E virus-like particle as a carrier for oral-delivery

AU - Jariyapong, Pitchanee

AU - Xing, Li

AU - van Houten, Nienke E.

AU - Li, Tian Cheng

AU - Weerachatyanukul, Wattana

AU - Hsieh, Benjamin

AU - Moscoso, Carlos G.

AU - Chen, Chun Chieh

AU - Niikura, Masahiro

AU - Cheng, Holland H R

PY - 2013/1/2

Y1 - 2013/1/2

N2 - Oral delivery with virus-like particles (VLPs) is advantageous because of the inherited entry pathway from their parental viral capsids, which enables VLP to withstand the harsh and enzymatic environment associated with human digestive tract. However, the repeat use of this system is challenged by the self-immunity. In order to overcome this problem, we engineered the recombinant capsid protein of hepatitis E virus by inserting p18 peptide, derived from the V3 loop of HIV-1 gp120, into the antibody-binding site. The chimeric VLP resembled the tertiary and quaternary structures of the wild type VLP and specifically reacted with an HIV-1 antibody against V3 loop. Different from the wild type VLP, the chimeric VLP was vulnerable to trypsin cleavage although it appeared as intact particle, suggesting that the intermolecular forces of attraction between the recombinant capsid proteins are strong enough to maintain the VLP icosahedral arrangement. Importantly, this VLP containing the V3 loop did not react with anti-HEV antibodies, in correspondence to the mutation at its antibody-binding site. Therefore, the insertion of peptides at the surface antigenic site could allow VLPs to escape pre-existing anti-HEV humoral immunity.

AB - Oral delivery with virus-like particles (VLPs) is advantageous because of the inherited entry pathway from their parental viral capsids, which enables VLP to withstand the harsh and enzymatic environment associated with human digestive tract. However, the repeat use of this system is challenged by the self-immunity. In order to overcome this problem, we engineered the recombinant capsid protein of hepatitis E virus by inserting p18 peptide, derived from the V3 loop of HIV-1 gp120, into the antibody-binding site. The chimeric VLP resembled the tertiary and quaternary structures of the wild type VLP and specifically reacted with an HIV-1 antibody against V3 loop. Different from the wild type VLP, the chimeric VLP was vulnerable to trypsin cleavage although it appeared as intact particle, suggesting that the intermolecular forces of attraction between the recombinant capsid proteins are strong enough to maintain the VLP icosahedral arrangement. Importantly, this VLP containing the V3 loop did not react with anti-HEV antibodies, in correspondence to the mutation at its antibody-binding site. Therefore, the insertion of peptides at the surface antigenic site could allow VLPs to escape pre-existing anti-HEV humoral immunity.

KW - Hepatitis E virus

KW - HIV-1 epitope

KW - Quaternary structure

KW - Recombinant capsid protein

KW - Trypsin proteolysis

KW - Virus like particle

UR - http://www.scopus.com/inward/record.url?scp=84871376730&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871376730&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2012.10.073

DO - 10.1016/j.vaccine.2012.10.073

M3 - Article

C2 - 23107594

AN - SCOPUS:84871376730

VL - 31

SP - 417

EP - 424

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 2

ER -